vadimezan has been researched along with 3,4-dihydroxy-xanthone in 1 studies
| Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (3,4-dihydroxy-xanthone) | Trials (3,4-dihydroxy-xanthone) | Recent Studies (post-2010) (3,4-dihydroxy-xanthone) |
|---|---|---|---|---|---|
| 272 | 16 | 101 | 6 | 0 | 3 |
| Protein | Taxonomy | vadimezan (IC50) | 3,4-dihydroxy-xanthone (IC50) |
|---|---|---|---|
| Tyrosinase | Homo sapiens (human) | 5.12 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 1.89 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Jiang, Z; Liu, J; Liu, Z; Wang, H; Zhang, C; Zhang, J | 1 |
1 other study(ies) available for vadimezan and 3,4-dihydroxy-xanthone
| Article | Year |
|---|---|
Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
Topics: Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Proto-Oncogene Proteins c-mdm2; Tumor Suppressor Protein p53; Xanthones | 2017 |